View Post

Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 Mutations

In Clinical Trials by Barbara Jacoby

By: Rachel Narozniak From: onclive.com Poziotinib, a novel drug that targets relatively uncommon EGFR and HER2 exon 20 insertion mutations, is being tested in a biomarker-driven trial of patients with non–small cell lung cancer (NSCLC) in both second-line and treatment-naïve settings. The phase II ZENITH20 trial (NCT03318939) is evaluating poziotinib monotherapy, an orally available agent, across 7 cohorts based on …

View Post

Novel Approaches Push the Envelope in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jessica Hergert From: onclive.com Developments in antibody-drug conjugates (ADCs), TKIs, and neoadjuvant interventions are improving outcomes for patients with early- and advanced-stage HER2-positive breast cancer, said Douglas K. Marks, MD, adding that investigational approaches could expand the treatment armamentarium even further. “For the treating oncologists, the options to offer patients who previously had a very poor prognosis are becoming …

View Post

Weight-loss drug could fight resistant lung cancer

In In The News by Barbara Jacoby

Posted by National University of Singapore From: futurity.org New research could pave the way for using versions of an existing drug to keep lung cancer cells from becoming drug-resistant. Researchers have discovered that a key enzyme in lipid metabolism controls the response to a class of targeted drugs called tyrosine kinase inhibitors (TKIs) in lung cancer. Cells use nutrients such …